Endometriosis Treatment Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Endometriosis treatment revenue is concentrated across pharmacologic therapies, with hormonal agents and GnRH antagonists forming the commercial backbone of the category. Branded drugs such as AbbVie's Orilissa (elagolix) and Pfizer/Myovant's Myfembree (relugolix) have reshaped the prescription landscape since their respective approvals. Pain management, post-surgical adjuvant therapy, and emerging non-hormonal pipelines round out the product mix.

• •Global market valued at approximately USD 2.08 billion in 2025 with an 11.76% CAGR through the early 2030s.
• •Orilissa and Myfembree/Ryeqo are among the leading branded therapeutics driving current revenue.
• •Standard of care combines NSAIDs, hormonal contraceptives, GnRH antagonists, and laparoscopic surgery.

The most important tailwinds are rising diagnosis rates, longer durations of pharmacologic treatment, and the global push to treat endometriosis as a chronic disease rather than a one-off surgical event. Pharmaceutical investment in non-hormonal mechanisms and patient-friendly dosing is also expanding the addressable population.

• •Improved imaging, biomarker research, and reduced diagnostic delay are increasing the treated patient pool.
• •Expanded approvals of once-daily oral GnRH antagonists are supporting longer-term prescription use.
• •Government and advocacy initiatives are pushing for earlier intervention and better insurance coverage.

The market is typically segmented by treatment type (hormonal therapy, pain management, GnRH modulators, surgery), drug (Orilissa, Myfembree/Ryeqo, Lupron, Visanne, and others), and distribution channel (hospital, retail, and online pharmacy). North America leads on revenue per patient due to pricing and reimbursement, while Asia-Pacific is the fastest-growing region as awareness and women's health infrastructure expand.

• •Hormonal therapy and GnRH antagonists make up the largest revenue share within the treatment mix.
• •North America accounts for the dominant share of global spending; Asia-Pacific is the fastest-growing region.
• •Hospital pharmacies lead distribution today, but online and specialty pharmacies are gaining ground.

What are the recent trends and outlook?

The next phase of growth will be defined by non-hormonal drug candidates, AI-assisted diagnosis, and digital symptom-tracking tools that together shorten the time to treatment. Commercial focus is also shifting toward combination regimens and recurrence-prevention strategies, which should extend the duration of pharmacologic therapy per patient.

• •Non-hormonal and GnRH receptor antagonists with improved tolerability are the leading pipeline themes.
• •Adoption of AI imaging and biomarker-based diagnostics is expected to expand the treated population.
• •Combination therapies and long-term disease management are likely to lift average revenue per patient over the decade.